Hepatitis C virus prevalence and genotyping among hepatocellular carcinoma patients in Baghdad

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 18, 2014, Pages 7725-7730

  Al Kubaisy, Waqar Abd Al Qahar ^a   Obaid, Kadhim Jawad ^a   Mohd Noor, Nor Aini ^a   Binti Nik Ibrahim, Nik Shamsidah ^a   Al Azawi, Ahmed Albu Kareem ^b  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HCV markers; Hepatitis C virus; Hepatocellular carcinoma; Iraq

Indexed keywords

VIRUS RNA;

AGED; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; IRAQ; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTOR; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IRAQ; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; RNA, VIRAL;

EID: 84908042356     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.18.7725     Document Type: Article

References (51)

1. Abd El-Rahman NZ, Nabawy Z, Auhood AMN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev, 14, 6721-26.
2. Aghemo A and Colombo M (2013). Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol, 35, 111-20.
3. Al Kubaisy W (1998). Epidemiology and genotypic distribution of hepatitis C in Iraqi pregnant women. Thesis for degree of doctor in philosophy. Baghdad-Iraq.
4. Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91.
5. Amal AM, Samah AL, James DC, Abdel Gawad MH, Ibrahem S (2011). Chronic hepatitis C genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virology J, 8, 496.
6. Anita C, Gaurav D, Vikas V, Amit PS (2011). Distribution pattern of HCV genotypes and its association with viral load. Indian J Med Res, 133, 326-31.
7. Berry V, Arora R, Paul P (2005). Hepatitis C-clinical outcome and. diagnosis. J K Sci, 7, 129-32.
8. Chayama K, Tsubota A, Kobayashi M, et al (1997). Pretreatment virus load and multiple amino acid substitution in the interferon treatment in patients with chronic genotypes 1b hepatitis C virus infection. Hepatology, 25, 745-9.
9. David RM, Stanley ML (2011). Virus-specific Mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene, 28, 1969-83.
10. Denis S, Abdelouahid EK, Hanan G, et al (2012). Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol, 4, 342-55.
11. Donato F, Tagger A, Gelatti U, et al (2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155, 323-31.
12. El-Serag HB, Mason AC (2000). Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med.;160 (21): 3227-30.
13. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
14. El-Serag HB (2002). Hepatocellular carcinoma and hepatitis C in the United States. Hepatology, 36, 74-83.
15. Esaki T, Suzuki N, Yokoyama K, et al (2004). Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV tests but positive liver tissue HCV RNA. Intern Med, 43, 279-82.
16. Farinati F, Cardin R, Bortolami M, et al (2007). Hepatitis C virus: From oxygen free radicals to hepatocellular carcinoma. J Viral Hepat, 14, 821-9.
17. Farrell G (2002). Hepatitis C, other liver disorders, and liver health: a practical guide. sydney: maclennan and petty.
18. Fujioka S, Shimomura H, Iwasaki Y, et al (2003). Hepatitis B virus gene in liver tissue promotes hepatocellular carcinoma development in chronic hepatitis C patients. Dig Dis Sci, 48, 1920-4.
19. Hirakawa M, Ikeda K, Arase Y, et al (2008). Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med, 47, 1637-43.
20. Hossein K, Mehdi F, Seyed HRM, Hamid RM (2012). Hepatitis C virus-proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5917-35.
21. Jen-Eing J, Meng-Feng T, Hey-Ru T, et al (2014). Impact of hepatitis B and hepatitis C on adverse hepatitis fibrosis in hepatocellular carcinoma related to betel quid chewing. Asian Pac J Cancer Prev, 15, 637-42.
22. Jian-Ying Z, Min D, Xiao W, et al (1998). A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol, 27, 574-8.
23. Jin-Hu F, Jian-Bing W, Yong J, et al (2013). Attributable causes of liver cancer. Asian Pac J Cancer Prev, 14, 7251-56.
24. Kazuo T, Shoji T (1997). Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alonine aminotransferase levels in hepatoctomized patient with hepatitis C virus associated cirrhosis and HCC. Cancer, 79, 688-94.
25. Kew MC, Yu MC, Kedda MA, et al (1997). The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology, 112, 184-7.
26. Koike K (2007). Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol, 22, 108-11.
27. Levrero M (2006). Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene, 25, 3834-47.
28. th ed. philadelphia: lippincott-raven.
29. Lok AS (2011). Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology, 140, 840-9.
30. Moutaz D, Aliaa A (2009). Hepatocellular carcinoma in hepatitis c genotype 4 after viral clearance and in absence of cirrhosis: two case reports. Case Report Cases J, 2, 7927.
31. Nelson PK, Mathers BM, Cowie B, et al (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378, 571-83.
32. Nishioka K, Watanabe J, Furuta S, et al (1991). A high prevalence of antibodies to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer, 67, 429-33.
33. Nousbaum JB, Pol S, Nalpas B, et al (1995). Hepatitis C virus type 1b (II) infection in France and Italy. collaborative study group. Ann Intern Med, 122, 161-8.
34. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
35. Peng C, You C, Mei XS, et al (2012). Bicluster and pathway enrichment analysis of HCV-induced cirrhosis and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 3741-45.
36. Rathi PK, Lucinda LH, Lauren EE, Stanley ML, David RM (2011). Hepatitis C Virus Infection causes cell cycle arrest at the level of initiation of mitosis. J Virol, 85, 7989-8001.
37. Rivas-Estilla AM, Cordero-Perez P, Trujillo-Murillo KC, et al (2008). Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. Ann Hepatol, 7, 144-7.
38. Ruiz J, Sangro B, Cuende JI, et al (1992). Hepatitis B and C viral infections in patients with hepatocellular cardnoma. Hepatology, 16, 637-41.
39. Samreen B, Khaliq S, Ashfaq UA, et al (2012). Hepatitis C virus entry: role of host and viral factors. Infect Genet Evol, 12, 1699-709.
40. Sangiovanni A, Del Ninno E, Fasani P, et al (2004). Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 126, 1005-14.
41. Savino B, Daniela S, Piero LA, et al (2011). Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med, 3, 21-8.
42. Sherman M (2005). Hepatocellular carcinoma: epidemiology, risk factors and screening. Semin Liver Dis, 25, 143-54.
43. Shiratori Y, Imazeki F, Moriyama M, et al (2000). Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med, 132, 517-24.
44. Simmonds P, Alberti A, Alter HJ, et al (1994). A proposal system for the nomenclature of hepatitis C viral genotypes. Hepatology, 19, 1321-4.
45. Takano S, Yokosuka O, Imazeld F, et al (1995). Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology, 21, 650-5.
46. Takeshi T, Kazuhiro N, Akiko S, et al (2012). Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol, 27, 797-804.
47. Tanaka Y, Hanada K, Mizokami M, et al (2002). Inaugural article: a comparison of the molecular clock of hepatitis C virus in the US and Japan. Proc Natl AcadSci USA, 99, 15584-9.
48. Tornesello ML, Buonaguro L, Tatangelo F, et al (2013). Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics, 102, 74-83.
49. Willatt JM, Hussain HK, Adusumilli S, et al (2008). MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology, 247, 311-30.
50. Yang JD, Roberts LR (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol, 7, 448-58.
51. Yu MC, Tong MJ, Coursaget P, et al (1990). Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the US. J Natl Cancer Inst, 82, 1038-61.